HER2 Support Group Forums - for those considering/undergoing neoadjuvant treatments, longterm statistics !!!!

based on presence/absence of in- breast & axillary pCR

[JAMA Oncology]

April 2016, Vol 2, No. 4 >

Original Investigation | April 2016
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy

Sarah S. Mougalian, MD1; Mike Hernandez, MS2; Xiudong Lei, PhD2; Siobhan Lynch, MD3; Henry M. Kuerer, MD, PhD4; William F. Symmans, MD5; Richard L. Theriault, DO6; Bruno D. Fornage, MD7; Limin Hsu, MS6; Thomas A. Buchholz, MD8; Aysegul A. Sahin, MD5; Kelly K. Hunt, MD4; Wei Tse Yang, MD7; Gabriel N. Hortobagyi, MD6; Vicente Valero, MD6
[+] Author Affiliations

JAMA Oncol. 2016;2(4):508-516. doi:10.1001/jamaoncol.2015.4935. Text Size: A A A

ABSTRACT

Importance The long-term effect of axillary pathologic complete response (pCR) on survival among women with breast cancer treated with primary systemic chemotherapy (PST) is unknown.

Objective To assess the long-term effect of axillary pCR on relapse-free survival (RFS) and overall survival (OS) in women with breast cancer with cytologically confirmed axillary lymph node metastases treated with PST.

Design, Setting, and Participants We retrospectively analyzed the effect of axillary pCR on 10-year OS and RFS among all women who received a diagnosis of breast cancer stages II to III with cytologically confirmed axillary metastases between 1989 and 2007 who received PST at a large US comprehensive cancer center. Women were stratified by post-PST axillary status, and survival outcomes were estimated and compared according to response in the breast and axilla.

Main Outcomes and Measures Outcomes of interest were RFS and OS.

Results Of 1600 women treated, median (range) age at diagnisis was 49 (21-86) years. A total of 454 (28.4%) achieved axillary pCR. These patients were more likely to have human epidermal growth factor receptor 2 (HER2)-positive and triple-negative disease (P < .001), pCR in the breast (P < .001), high-grade tumors (P < .001), and lower clinical and pathologic T stage (P = .002). Ten-year OS rates were 84% (95% CI, 79%-88%) and 57% (95% CI, 54%-61%) (P < .001) and 10-year RFS rates 79% (95% CI, 74%-83%) and 50% (95% CI, 46%-53%) (P < .001) for patients with axillary pCR and residual axillary disease, respectively. For patients with axillary pCR, 10-year OS rates were 90% (95% CI, 84%-94%) for those with breast pCR and 72% (95% CI, 61%-80%) for those with residual breast disease (P < .001). For patients with residual axillary disease, 10-year OS rates were 66% (95% CI, 56%-74%) for patients with and 56% (95% CI, 52%-60%) for patients without breast pCR (P = .02). Of patients receiving HER2-targeted therapy for HER2-positive disease, 67.1% (100 of 149) achieved axillary pCR; 10-year OS rates were 92% (95% CI, 84%-96%) and 57% (95% CI, 20%-82%) (P = .003) and 10-year RFS rates 89% (95% CI, 81%-94%) and 44% (95% CI, 18%-68%) (P < .001) for those with axillary pCR and residual axillary disease, respectively.

Conclusions and Relevance Axillary pCR was associated with improved 10-year OS and RFS. Patients with axillary and breast pCR after PST had superior long-term survival outcomes. Patients undergoing HER2-targeted therapy for HER2-positive disease had high rates of axillary pCR, and those with axillary pCR had excellent 10-year OS.